Premium
Intravenous administration of 9‐aminocamptothecin to dogs with lymphoma
Author(s) -
Moore A. S.,
Imondi A. R.,
De Souza P. L.,
Wood C. A.
Publication year - 2003
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1046/j.1476-5829.2003.00012.x
Subject(s) - medicine , neutropenia , lymphoma , canine lymphoma , chemotherapy , gastroenterology , limiting , anesthesia , engineering , mechanical engineering
A colloidal dispersion formulation of 9‐aminocamptothecin (9‐AC) was administered intravenously to 10 dogs with previously untreated, spontaneously occurring, multicentric lymphoma. The dogs received a 72‐h infusion of 9‐AC at a rate of 46.5–51.25 µg m −2 h −1 (total dose range 3.35–3.69 mg m −2 ). This dose range was associated with myelosuppression, consisting principally of neutropenia with a nadir at 7 days following the start of infusion. Neutropenia and thrombocytopenia were the most common toxicoses and are most likely to be dose‐limiting toxicities; low‐grade gastrointestinal signs were rarely seen. Concentrations of 9‐AC lactone, as well as clinical toxicities, compare favourably with those found in humans. Tumour responses were seen in all treated dogs. Response to other chemotherapy, following cessation of 9‐AC treatment, was not obviously compromised even in dogs clinically resistant to 9‐AC. 9‐AC is a novel treatment drug for canine lymphoma, which appears to show great promise.